Cardiac thromboxane A2 receptor activation does not directly induce cardiomyocyte hypertrophy but does cause cell death that is prevented with gentamicin and 2-APB

BMC Pharmacology and Toxicology

Volumn 15, Issue 1, 2014, Pages

  Touchberry, Chad D ^b   Silswal, Neerupma ^a   Tchikrizov, Vladimir ^a   Elmore, Christopher J ^a   Srinivas, Shubra ^a   Akthar, Adil S ^a   Swan, Hannah K ^c   Wetmore, Lori A ^c   Wacker, Michael J ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MEMPHIS   (United States)

^c WILLIAM JEWELL COLLEGE   (United States)

Author keywords

Cardiomyocytes; Cardiovascular disease; IP3; TP receptor; TXA2; U46619

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 AMINOETHYL DIPHENYLBORATE; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ALPHA SMOOTH MUSCLE ACTIN; ATRIAL NATRIURETIC FACTOR; GENTAMICIN; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; MYOSIN HEAVY CHAIN BETA; PROTEIN INHIBITOR; THROMBOXANE A2 RECEPTOR; UNCLASSIFIED DRUG; 2-AMINOETHYL DIPHENYLBORINATE; BORON DERIVATIVE; MESSENGER RNA; MUSCLE PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL DEATH; CELL SIZE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; FLOW CYTOMETRY; GENE EXPRESSION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; MALE; MOUSE; MTT ASSAY; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; ANIMAL; CARDIOMEGALY; CELL LINE; DRUG EFFECTS; GENETICS; HEART MUSCLE; METABOLISM;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; BORON COMPOUNDS; CARDIOMEGALY; CELL DEATH; CELL LINE; CELLS, CULTURED; GENTAMICINS; MALE; MICE; MUSCLE PROTEINS; MYOCARDIUM; MYOCYTES, CARDIAC; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; RNA, MESSENGER;

EID: 84924363801     PISSN: 20506511     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/2050-6511-15-73     Document Type: Article

References (68)

1. Graziani F, Biasucci LM, Cialdella P, Liuzzo G, Giubilato S, Della Bona R, Pulcinelli FM, Iaconelli A, Mingrone G, Crea F: Thromboxane production in morbidly obese subjects. Am J Cardiol 2011, 107:1656-1661. 10.1016/j.amjcard.2011.01.053
2. Takayama K, Yuhki K, Ono K, Fujino T, Hara A, Yamada T, Kuriyama S, Karibe H, Okada Y, Takahata O, Taniguchi T, Iijima T, Iwasaki H, Narumiya S, Ushikubi F: Thromboxane A2 and prostaglandin F2alpha mediate inflammatory tachycardia. Nat Med 2005, 11:562-566. 10.1038/nm1231
3. Coker SJ, Parratt JR, Ledingham IM, Zeitlin IJ: Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature 1981, 291:323-324. 10.1038/291323a0
4. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT: Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981, 304:685-691. 10.1056/NEJM198103193041201
5. Montalescot G, Drobinski G, Maclouf J, Maillet F, Salloum J, Ankri A, Kazatchkine M, Eugene L, Thomas D, Grosgogeat Y: Evaluation of thromboxane production and complement activation during myocardial ischemia in patients with angina pectoris. Circulation 1991, 84:2054-2062. 10.1161/01.CIR.84.5.2054
6. Moncada S, Vane JR: Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1978, 30:293-331.
7. Hamberg M, Svensson J, Samuelsson B: Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 1975, 72:2994-2998. 10.1073/pnas.72.8.2994
8. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, Fitzgerald D, Hirsh J, Husted S, Kvasnicka J, Montalescot G, Garcia Rodriguez LA, Verheugt F, Vermylen J, Wallentin L, Priori SG, Alonso Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Fernandez Burgos E, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Ferreira R, et al.: Expert consensus document on the use of antiplatelet agents: the task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004, 25:166-181. 10.1016/j.ehj.2003.10.013
9. Wacker MJ, Tehrani RN, Smoot RL, Orr JA: Thromboxane A(2) mimetic evokes a bradycardia mediated by stimulation of cardiac vagal afferent nerves. Am J Physiol Heart Circ Physiol 2002, 282:H482-H490.
10. Wacker MJ, Best SR, Kosloski LM, Stachura CJ, Smoot RL, Porter CB, Orr JA: Thromboxane A2-induced arrhythmias in the anesthetized rabbit. Am J Physiol Heart Circ Physiol 2006, 290:H1353-H1361.
11. Baldassare JJ, Tarver AP, Henderson PA, Mackin WM, Sahagan B, Fisher GJ: Reconstitution of thromboxane A2 receptor-stimulated phosphoinositide hydrolysis in isolated platelet membranes: involvement of phosphoinositide-specific phospholipase C-beta and GTP-binding protein Gq. Biochem J 1993,291(Pt 1):235-240.
12. Dorn GW II, Becker MW: Thromboxane A2 stimulated signal transduction in vascular smooth muscle. J Pharmacol Exp Ther 1993, 265:447-456.
13. Huang JS, Ramamurthy SK, Lin X, Le Breton GC: Cell signalling through thromboxane A2 receptors. Cell Signal 2004, 16:521-533. 10.1016/j.cellsig.2003.10.008
14. Shenker A, Goldsmith P, Unson CG, Spiegel AM: The G protein coupled to the thromboxane A2 receptor in human platelets is a member of the novel Gq family. J Biol Chem 1991, 266:9309-9313.
15. Walsh M, Foley JF, Kinsella BT: Investigation of the role of the carboxyl-terminal tails of the alpha and beta isoforms of the human thromboxane A(2) receptor (TP) in mediating receptor:effector coupling. Biochim Biophys Acta 2000, 1496:164-182. 10.1016/S0167-4889(00)00031-8
16. Wacker MJ, Kosloski LM, Gilbert WJ, Touchberry CD, Moore DS, Kelly JK, Brotto M, Orr JA: Inhibition of thromboxane A2-induced arrhythmias and intracellular calcium changes in cardiac myocytes by blockade of the inositol trisphosphate pathway. J Pharmacol Exp Ther 2009, 331:917-924. 10.1124/jpet.109.157677
17. Nakamura F, Minshall RD, Le Breton GC, Rabito SF: Thromboxane A2 mediates the stimulation of inositol 1,4,5-trisphosphate production and intracellular calcium mobilization by bradykinin in neonatal rat ventricular cardiomyocytes. Hypertension 1996, 28:444-449. 10.1161/01.HYP.28.3.444
18. Dogan S, Turnbaugh D, Zhang M, Cofie DQ, Fugate RD, Kem DC: Thromboxane A2 receptor mediation of calcium and calcium transients in rat cardiomyocytes. Life Sci 1997, 60:943-952. 10.1016/S0024-3205(97)00024-6
19. Hoffmann P, Heinroth-Hoffmann I, Toraason M: Alterations by a thromboxane A2 analog (U46619) of calcium dynamics in isolated rat cardiomyocytes. J Pharmacol Exp Ther 1993, 264:336-344.
20. Ter Keurs HE, Boyden PA: Calcium and arrhythmogenesis. Physiol Rev 2007, 87:457-506. 10.1152/physrev.00011.2006
21. Bers DM, Guo T: Calcium signaling in cardiac ventricular myocytes. Ann N Y Acad Sci 2005, 1047:86-98. 10.1196/annals.1341.008
22. Mudd JO, Kass DA: Tackling heart failure in the twenty-first century. Nature 2008, 451:919-928. 10.1038/nature06798
23. Harr MW, Distelhorst CW: Apoptosis and autophagy: decoding calcium signals that mediate life or death. Cold Spring Harbor Perspect Biol 2010, 2:a005579.
24. Lin H, Li HF, Lian WS, Chen HH, Lan YF, Lai PF, Cheng CF: Thromboxane A2 mediates iron-overload cardiomyopathy in mice through calcineurin-nuclear factor of activated T cells signaling pathway. Circ J Off J Jpn Circ Soc 2013, 77:2586-2595.
25. Wang Y, Li C, Liu Z, Shi T, Wang Q, Li D, Wu Y, Han J, Guo S, Tang B, Wang W: DanQi Pill protects against heart failure through the arachidonic acid metabolism pathway by attenuating different cyclooxygenases and leukotrienes B4. BMC Complement Altern Med 2014, 14:67. 10.1186/1472-6882-14-67
26. Zhang Z, Vezza R, Plappert T, McNamara P, Lawson JA, Austin S, Pratico D, Sutton MS, FitzGerald GA: COX-2-dependent cardiac failure in Gh/tTG transgenic mice. Circ Res 2003, 92:1153-1161. 10.1161/01.RES.0000071749.22027.45
27. Lai J, Jin H, Yang R, Winer J, Li W, Yen R, King KL, Zeigler F, Ko A, Cheng J, Bunting S, Paoni NF: Prostaglandin F2 alpha induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. Am J Physiol 1996, 271:H2197-H2208.
28. Shizukuda Y, Buttrick PM: Protein kinase C-zeta modulates thromboxane A(2)-mediated apoptosis in adult ventricular myocytes via Akt. Am J Physiol Heart Circ Physiol 2002, 282:H320-H327.
29. Touchberry CD, Green TM, Tchikrizov V, Mannix JE, Mao TF, Carney BW, Girgis M, Vincent RJ, Wetmore LA, Dawn B, Bonewald LF, Stubbs JR, Wacker MJ: FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab 2013, 304:E863-E873. 10.1152/ajpendo.00596.2012
30. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, Izzo NJ Jr: HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A 1998, 95:2979-2984. 10.1073/pnas.95.6.2979
31. Hong HM, Song EJ, Oh E, Kabir MH, Lee C, Yoo YS: Endothelin-1-and isoproterenol-induced differential protein expression and signaling pathway in HL-1 cardiomyocytes. Proteomics 2011, 11:283-297. 10.1002/pmic.201000018
32. Kang BY, Khan JA, Ryu S, Shekhar R, Seung KB, Mehta JL: Curcumin reduces angiotensin II-mediated cardiomyocyte growth via LOX-1 inhibition. J Cardiovasc Pharmacol 2010, 55:417-424. 10.1097/FJC.0b013e3181ca4ba1
33. Brunt KR, Tsuji MR, Lai JH, Kinobe RT, Durante W, Claycomb WC, Ward CA, Melo LG: Heme oxygenase-1 inhibits pro-oxidant induced hypertrophy in HL-1 cardiomyocytes. Exp Biol Med 2009, 234:582-594. 10.3181/0810-RM-312
34. Chandrasekar B, Mummidi S, Claycomb WC, Mestril R, Nemer M: Interleukin-18 is a pro-hypertrophic cytokine that acts through a phosphatidylinositol 3-kinase-phosphoinositide-dependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes. J Biol Chem 2005, 280:4553-4567. 10.1074/jbc. M411787200
35. Jehle J, Staudacher I, Wiedmann F, Schweizer P, Becker R, Katus H, Thomas D: Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid. Br J Pharmacol 2012, 167:1563-1572. 10.1111/j.1476-5381.2012.02117.x
36. Andersen AD, Poulsen KA, Lambert IH, Pedersen SF: HL-1 mouse cardiomyocyte injury and death after simulated ischemia and reperfusion: roles of pH, Ca2+-independent phospholipase A2, and Na+/H+ exchange. Am J Physiol Cell Physiol 2009, 296:C1227-C1242. 10.1152/ajpcell.00370.2008
37. Gonzalez-Juanatey JR, Iglesias MJ, Alcaide C, Pineiro R, Lago F: Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of alpha1-adrenergic blockade. Circulation 2003, 107:127-131. 10.1161/01.CIR.0000043803.20822.D1
38. Kitta K, Day RM, Ikeda T, Suzuki YJ: Hepatocyte growth factor protects cardiac myocytes against oxidative stress-induced apoptosis. Free Radic Biol Med 2001, 31:902-910. 10.1016/S0891-5849(01)00663-3
39. Touchberry CD, Elmore CJ, Nguyen TM, Andresen JJ, Zhao X, Orange M, Weisleder N, Brotto M, Claycomb WC, Wacker MJ: Store-operated calcium entry is present in HL-1 cardiomyocytes and contributes to resting calcium. Biochem Biophys Res Commun 2011, 416:45-50.
40. Touchberry CD, Bales IK, Stone JK, Rohrberg TJ, Parelkar NK, Nguyen T, Fuentes O, Liu X, Qu CK, Andresen JJ, Valdivia HH, Brotto M, Wacker MJ: Phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2) potentiates cardiac contractility via activation of the ryanodine receptor. J Biol Chem 2010, 285:40312-40321. 10.1074/jbc. M110.179689
41. Dhanasekaran A, Gruenloh SK, Buonaccorsi JN, Zhang R, Gross GJ, Falck JR, Patel PK, Jacobs ER, Medhora M: Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am J Physiol Heart Circ Physiol 2008, 294:H724-H735. 10.1152/ajpheart.00979.2007
42. Hirsh PD, Firth BG, Campbell WB, Dehmer GJ, Willerson JT, Hillis LD: Effects of provocation on transcardiac thromboxane in patients with coronary artery disease. Am J Cardiol 1983, 51:727-733. 10.1016/S0002-9149(83)80123-4
43. Hirsh PD, Firth BG, Campbell WB, Willerson JT, Hillis LD: Influence of blood sampling site and technique on thromboxane concentrations in patients with ischemic heart disease. Am Heart J 1982, 104:234-237. 10.1016/0002-8703(82)90198-3
44. Neri Serneri GG, Gensini GF, Abbate R, Prisco D, Rogasi PG, Laureano R, Casolo GC, Fantini F, Di Donato M, Dabizzi RP: Abnormal cardiocoronary thromboxane A2 production in patients with unstable angina. Am Heart J 1985, 109:732-738. 10.1016/0002-8703(85)90631-3
45. Santilli F, Davi G, Basili S, Lattanzio S, Cavoni A, Guizzardi G, De Feudis L, Traisci G, Pettinella C, Paloscia L, Minuz P, Meneguzzi A, Ciabattoni G, Patrono C: Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. J Thromb Haemost JTH 2010, 8:914-922.
46. Chu LM, Robich MP, Bianchi C, Feng J, Liu Y, Xu SH, Burgess T, Sellke FW: Effects of cyclooxygenase inhibition on cardiovascular function in a hypercholesterolemic swine model of chronic ischemia. Am J Physiol Heart Circ Physiol 2012, 302:H479-H488. 10.1152/ajpheart.00146.2011
47. Robich MP, Chu LM, Burgess TA, Feng J, Bianchi C, Sellke FW: Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on myocardial function and perfusion. J Cardiovasc Pharmacol 2011, 57:122-130. 10.1097/FJC.0b013e3182010a96
48. Francois H, Athirakul K, Howell D, Dash R, Mao L, Kim HS, Rockman HA, Fitzgerald GA, Koller BH, Coffman TM: Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab 2005, 2:201-207. 10.1016/j.cmet.2005.08.005
49. LaPointe MC, Mendez M, Leung A, Tao Z, Yang XP: Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ physiol 2004, 286:H1416-H1424.
50. Lasserre B, Huu AP, Navarro-Delmasure C, Dossou-Gbete V: Binding of a thromboxane A2 (TXA2)/prostaglandin H2 (PGH2) receptor antagonist to rabbit and pig heart membrane protein. Prostaglandins Leukot Essent Fat Acids 1992, 47:153-157. 10.1016/0952-3278(92)90153-A
51. Bowling N, Dube GP, Kurtz WL, Brune KA, Saussy DL Jr, Dorn GW 2nd, Mais DE: Characterization of thromboxane A2/prostaglandin H2 binding sites in guinea pig cardiac membrane preparations. J Mol Cell Cardiol 1994, 26:915-923. 10.1006/jmcc.1994.1109
52. Li Y, Kang JX, Leaf A: Differential effects of various eicosanoids on the production or prevention of arrhythmias in cultured neonatal rat cardiac myocytes. Prostaglandins 1997, 54:511-530.
53. Yatani A, Frank K, Sako H, Kranias EG, Dorn GW 2nd: Cardiac-specific overexpression of Galphaq alters excitation-contraction coupling in isolated cardiac myocytes. J Mol Cell Cardiol 1999, 31:1327-1336. 10.1006/jmcc.1999.0966
54. Dorn GW 2nd, Force T: Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005, 115:527-537. 10.1172/JCI24178
55. Gao Y, Yokota R, Tang S, Ashton AW, Ware JA: Reversal of angiogenesis in vitro, induction of apoptosis, and inhibition of AKT phosphorylation in endothelial cells by thromboxane A(2). Circ Res 2000, 87:739-745. 10.1161/01.RES.87.9.739
56. Jariyawat S, Takeda M, Kobayashi M, Endou H: Thromboxane A2 mediates cisplatin-induced apoptosis of renal tubule cells. Biochem Mol Biol Int 1997, 42:113-121.
57. Ushikubi F, Aiba Y, Nakamura K, Namba T, Hirata M, Mazda O, Katsura Y, Narumiya S: Thromboxane A2 receptor is highly expressed in mouse immature thymocytes and mediates DNA fragmentation and apoptosis. J Exp Med 1993, 178:1825-1830. 10.1084/jem.178.5.1825
58. Ramsammy LS, Josepovitz C, Kaloyanides GJ: Gentamicin inhibits agonist stimulation of the phosphatidylinositol cascade in primary cultures of rabbit proximal tubular cells and in rat renal cortex. J Pharmacol Exp Ther 1988, 247:989-996.
59. Jacobsen AN, Du XJ, Lambert KA, Dart AM, Woodcock EA: Arrhythmogenic action of thrombin during myocardial reperfusion via release of inositol 1,4,5-triphosphate. Circulation 1996, 93:23-26. 10.1161/01.CIR.93.1.23
60. Mackenzie L, Bootman MD, Laine M, Berridge MJ, Thuring J, Holmes A, Li WH, Lipp P: The role of inositol 1,4,5-trisphosphate receptors in Ca(2+) signalling and the generation of arrhythmias in rat atrial myocytes. J Physiol 2002, 541:395-409. 10.1113/jphysiol.2001.013411
61. Proven A, Roderick HL, Conway SJ, Berridge MJ, Horton JK, Capper SJ, Bootman MD: Inositol 1,4,5-trisphosphate supports the arrhythmogenic action of endothelin-1 on ventricular cardiac myocytes. J Cell Sci 2006, 119:3363-3375. 10.1242/jcs.03073
62. Chu WF, Sun HL, Dong DL, Qiao GF, Yang BF: Increasing intracellular calcium of guinea pig ventricular myocytes induced by platelet activating factor through IP3 pathway. Basic Clin Pharmacol Toxicol 2006, 98:104-109. 10.1111/j.1742-7843.2006.pto_313.x
63. Ibarra C, Estrada M, Carrasco L, Chiong M, Liberona JL, Cardenas C, Diaz-Araya G, Jaimovich E, Lavandero S: Insulin-like growth factor-1 induces an inositol 1,4,5-trisphosphate-dependent increase in nuclear and cytosolic calcium in cultured rat cardiac myocytes. J Biol Chem 2004, 279:7554-7565. 10.1074/jbc. M311604200
64. Zima AV, Blatter LA: Inositol-1,4,5-trisphosphate-dependent Ca(2+) signalling in cat atrial excitation-contraction coupling and arrhythmias. J Physiol 2004, 555:607-615. 10.1113/jphysiol.2003.058529
65. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR: Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008, 336:195-198. 10.1136/bmj.39430.529549.BE
66. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105:1650-1655. 10.1161/01.CIR.0000013777.21160.07
67. Halushka MK, Halushka PV: Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 2002, 105:1620-1622. 10.1161/01.CIR.0000015422.86569.52
68. Brothers TE, Robison JG, Elliott BM, Boggs JM, Halushka PV: Thromboxane A2 receptor density increases during chronic exposure to thromboxane A2 receptor antagonists after porcine carotid bypass. Cardiovasc Surg 1997, 5:92-98.